Stem Cell Headlines: Friday, 11/20

Advanced Cell Technology Files IND With FDA For First Human Clinical Trial Using Embryonic Stem Cells To Treat Eye Disease - 11.20.09

• Advanced Cell Technology, Inc. (OTCBB: ACTC) announced that it filed an Investigational New Drug (IND) Application with the US Food and Drug Administration (FDA) to initiate a Phase I/II multicenter study using embryonic stem cell derived retinal cells to treat patients with Stargardt's Macular Dystrophy (SMD).

 

U. of Nebraska Defeats Tighter Limits on Stem Cell Research - 11.20.09

• The University of Nebraska Board of Regents cast a tie vote on human embryonic stem cell research on Friday, defeating a rare effort to limit such research at a university system beyond what state and federal laws allow.

 

What's behind put activity in Osiris - 11.20.09

• As we close in on expiration at the end of today's session, traders are rolling out positions that they don't want to be without going into Monday. That's what we are seeing today in Osiris Therapeutics (OSIR), where traders are rolling put positions out a month.

 

Lab-grown Meat Could Solve Multiple Problems - 11.20.09

• Stem cell research has recently headed in innovative directions. Earlier this month scientists announced they had grown rabbit replacement penile erectile tissue. Now the idea of growing meat in the laboratory without animals is being proposed.

 

Epistem on acquisition trail after £2.9m placing - 11.20.09

• NORTH West biotechnology company Epistem has raised £2.9m through a placing of  720,000 shares at 400p. The fundraising will strengthen the Manchester firm's balance sheet, and give  it the firepower to make acquisitions.The AIM-listed stem cell research company, said the placed shares represented 10% of its entire share capital.

 

Stem Cell Therapeutics Corp. Announces Positive Review by Data Safety and Monitoring Board for the Phase IIb Stroke Trial Independent Committee approves progress of Phase IIb clinical stroke trial - 11.20.09

• Stem Cell Therapeutics Corp. ("SCT" or the "Company") (TSX VENTURE: SSS) announced today it has been advised by the Data Safety Monitoring Board ("DSMB") that a regularly scheduled safety analysis has been completed and the DSMB has recommended the Phase IIb stroke trial to continue as per the protocol.

 

Iowa City stem cell company gets state grant - 11.20.09

• Cellular Engineering Technologies of Iowa City received $50,000 from the state Thursday to develop a more efficient technology platform to make adult stem cells for use in medical research, drug development and clinical therapy.

 

WaferGen BioSystems Leases Space in Fremont - 11.19.09

• WaferGen Bio Systems Inc. (WGBS.OB) signed a 66-month lease for 19,186 square feet at 34781 Campus Drive in Fremont, CA.